Aclaris Therapeutics, Inc. (ACRS) Market Cap
Aclaris Therapeutics, Inc. has a market capitalization of $512.5M.
Financials based on reported quarter end 2025-12-31
Price: $4.25
▲ 0.27 (6.78%)
Market Cap: 512.53M
NASDAQ · time unavailable
CEO: Neal S. Walker
Sector: Healthcare
Industry: Medical - Diagnostics & Research
IPO Date: 2015-10-06
Website: https://www.aclaristx.com
Aclaris Therapeutics, Inc. (ACRS) - Company Information
Market Cap: 512.53M · Sector: Healthcare
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Analyst Sentiment
Based on 8 ratings
Analyst 1Y Forecast: $10.00
Average target (based on 3 sources)
Consensus Price Target
Low
$10
Median
$10
High
$10
Average
$10
Potential Upside: 135.3%
Price & Moving Averages
Related Companies in Healthcare
LEXEO THERAPEUTICS INC (LXEO)
Healthcare
$0.51B
Mkt Cap
PACIFIC BIOSCIENCES OF CALIFORNIA (PACB)
Healthcare
$0.51B
Mkt Cap
ORTHOFIX MEDICAL INC (OFIX)
Healthcare
$0.51B
Mkt Cap
FULGENT GENETICS INC (FLGT)
Healthcare
$0.51B
Mkt Cap
MIMEDX GROUP INC (MDXG)
Healthcare
$0.51B
Mkt Cap
VAREX IMAGING CORP (VREX)
Healthcare
$0.50B
Mkt Cap
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"ACRS reported revenue of $1.295M for the most recent quarter, with a net loss of $19.795M, resulting in an EPS of -$0.16. The company has total assets valued at $160.46M and liabilities of $57.38M, indicating a healthy equity position of $103.08M. Despite experiencing significant operating losses, the debt position appears favorable with a net debt of -$17.84M, suggesting a cash-rich position relative to its obligations. However, the company generated negative cash flow, with operating cash flow at -$13.13M and free cash flow at -$13.09M, reflecting ongoing financial challenges. ACRS saw a remarkable price appreciation of 94.12% over the past year, leading to favorable sentiment among investors despite the lack of dividend payouts. Overall, the financial metrics demonstrate a growth phase, albeit with considerable volatility in profitability and cash flow."
Revenue Growth
Minimal revenue growth is noted as the company is still establishing its market presence.
Profitability
The company is operating at a significant loss, impacting overall profitability.
Cash Flow Quality
Negative cash flow indicates ongoing liquidity issues.
Leverage & Balance Sheet
Strong equity position and negative net debt suggest manageable leverage.
Shareholder Returns
Strong price appreciation over the past year reflects positive shareholder sentiment.
Analyst Sentiment & Valuation
Analysts indicate a stable price target, reflecting cautious optimism.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Management’s Q1 message is upbeat on ATI-2138’s clinical direction and cash discipline, but the Q&A shows the pressure is on proving efficacy with a mechanism-specific edge. The company shifted ATI-2138 to a proof-of-concept Phase 2a in moderate-to-severe atopic dermatitis, using an open-label 12-week, 15-patient design with heavy pharmacodynamic marker work to isolate ITK’s contribution versus pure JAK3 effects. Dose is set at 10 mg BID (with ability to go higher), aiming for treatment response “north of” standard AD JAK inhibitors, though no explicit responder/endpoint targets were provided. On safety, they acknowledge black box risk but argue physicians have adapted and patients want fast disease relief. Financially, cash is $161M vs $182M at year-end with 0 debt; Q1 spend includes ~$14M nonrecurring items and burn should drop after Q2. Overall tone is confident, but analysts repeatedly probe dose/exposure rationale, comparative efficacy vs JAK competitors, and how the lack of placebo affects signal confidence.
Growth Catalysts
- Move ATI-2138 forward in a proof-of-concept Phase 2 in moderate-to-severe atopic dermatitis (switch from prior reevaluation of indication selection)
- ATI-2138 planned open-label 12-week, 15-patient study emphasizing PD markers to demonstrate ITK contribution
Business Development
- Mentions prior non-dilutive capital source strategy (no new deals disclosed on this call)
- Royalty/IP mentions: Lilly (baricitinib) and Sun Pharma (deuterated ruxolitinib from Concert) for alopecia areata method-of-use rights
Financial Highlights
- Cash/cash equivalents/marketable securities: $161M at Q1 end vs $182M at year-end
- 0 outstanding debt
- Q1 cash expenditures: ~$14M related to nonrecurring payments (discontinued R&D programs, severance from December RIF, and payments to third parties related to upfront under Sun Licensing Agreement)
- Management expects remaining 2024 quarterly cash expenditures to be significantly reduced vs Q1 (after nonrecurring items largely complete by Q2 2024)
- No explicit EPS or revenue guidance provided in the transcript
Capital Funding
- Cash runway implied by balance sheet: $161M cash equivalents/marketable securities
- No debt
- Burn described as “small” through end of year due to cost containment; balance sheet expected not to change appreciably through end of 2024
- No buyback/debt issuance disclosed
Strategy & Ops
- Cost containment initiatives on track; reduction in force announced in December referenced; discontinued program payments expected substantially completed by Q2 2024
- Clinical strategy shift: ATI-2138 proof-of-concept indication set to atopic dermatitis (moderate-to-severe) with PD-heavy design
Market Outlook
- Phase 2a topline timing: “definitely… within a year of this call” (back-end marker), with more color after first patient in
- No formal efficacy numeric targets provided beyond qualitative “north of” standard-of-care JAK inhibitors
Risks & Headheads
- Black box warning risk acknowledged for JAK inhibition (“you always have to think about… black box”); however management believes physician and sales experience suggests it is not a major hindrance once risks are explained
- Competitive efficacy bar in AD: management stated many patients do not achieve clear/near clear by Week 16 on dupilumab (60% not clear/near clear by Week 16; ~50% suboptimal response), implying need to outperform on efficacy
- Open-label design creates reliance on active arm/signal finding rather than placebo; management rationale is speed/cost efficiency rather than maximal statistical certainty
- Operational risk: timing depends on protocol/patient enrollment; no early topline guidance until after first patient in
Sentiment: CAUTIOUS
Note: This summary was synthesized by AI from the ACRS Q1 2024 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.